Commitments and Contingencies (Details) - USD ($)					1 Months Ended				6 Months Ended	12 Months Ended
	Sep. 01, 2021	Jul. 06, 2021	Jun. 01, 2021	Jan. 05, 2021	Jan. 27, 2022	Apr. 30, 2021	Jul. 31, 2020	Apr. 17, 2020	Jun. 30, 2022	Dec. 31, 2021	Feb. 01, 2022
Commitments and Contingencies (Details) [Line Items]
Employment agreement, description								The Employment Agreement provided for a base salary of $120,000 and 7,630,949 of vested shares of the Company’s common stock in April 2020. In addition, Mr. Weisblum shall be eligible to earn a bonus, subject to the sole discretion of the Company’s Board of Directors (“Board”).
Deferred compensation balance									$ 35,782
License fee		$ 10,000					$ 10,000
Commercial sale term									10 years
License agreement expire									15 years
Sublicense income, description									The Company or Company affiliates shall pay to UMB a percentage of all income received from its sublicensee as follows: (i) 25% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed before the filing of an NDA (or foreign equivalent) for the first licensed product; and (b) 15% of the Company’s sublicense income which is receivable with respect to any sublicense that is executed after the filing of an NDA (or foreign equivalent) for the first licensed product.
License agreement, description									the Company shall pay UMB; (i) a license fee, (ii) certain event-based milestone payments (see below for payment terms), (iii) royalty payments depending on net revenues (see below for payment terms), and (iv) a tiered percentage of sublicense income. The Company shall pay to UMB a license fee of $75,000, payable as follows: (a) $25,000 shall be due within 30 days following the effective date; and (b) $50,000 on or before the first anniversary of the effective date. The license fee is non-refundable and is not creditable against any other fee, royalty or payment. The Company shall be responsible for payment of all patent expenses in connection with preparing, filing, prosecution and maintenance of patents or patent applications relating to the patent rights. The Company paid $25,000 license fee on February 17, 2021 which was recorded as prepaid expense and is being amortized over the 15-year term. The Company recognized amortization expense of $4,375 in 2021. During the six months ended June 30, 2022, the Company recognized amortization expense of $2,500. At December 31, 2021, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $15,625. At June 30, 2022, prepaid expense and other current assets – current amounted $5,000 and prepaid expense – non-current amounts $13,125 as reflected in the accompanying condensed consolidated balance sheets.
Royalty payments, description									Royalty Payments Terms:  (i)3% on sales of licensed products (as defined in the Master License Agreement) during the applicable calendar year for sales less than $50,000,000; and
Prepaid expense and other current assets									$ 838	$ 838
Prepaid expenses non-current									10,615	$ 11,034
Non refundable fees									2,500
Non-refundable cash payment				$ 500,000					$ 500,000
Net sale percentage									2.00%
Licensor share (in Shares)				500					500
Aggregate of converted shares (in Shares)				625,000					625,000
Revenue term				15 years					15 years
Number of voting shares (in Shares)										20,000
Reverse stock split vote, description									(i) the date that the Reverse Stock Split Vote is approved by Aikido’s stockholders and (ii) December 31, 2021, at the option of the holder, into such number of shares of Aikido’s common stock determined by dividing the Stated Value by the Conversion Price. “Stated Value” means $1,000. “Conversion Price” means $0.80, subject to adjustment.Prior to the April 12, 2021, issuance of the common stock in lieu of the Series M Convertible Preferred Stock as discussed above, the Company valued the 500 Series M Convertible Preferred stock which was equivalent into Aikido’s 625,000 shares of common stock at a fair value of $0.85 per common share or $531,250 based quoted trading price of Aikido’s common stock on the date of grant. The Company recorded an equity investment of $531,250 (see Note 3) and deferred revenue of $531,250 to be recognized as revenues over the term of the license.
Deferred revenue									$ 1,031,250
Cash received									500,000
Securities received									531,250
Recognized revenues									34,375	$ 68,750
Deferred revenue current portion									68,750	68,750
Deferred revenue long-term portion									42,458	$ 893,750
Revenue long term portion amounts									$ 859,375
Consideration fee payable percentage									110.00%
Upfront license fees						$ 50,000			$ 50,000
First commercial sale									10 years
Agreement shall expire									15 years
Sponsored study agreement, description				The total cost under the Sponsored Study Agreement shall not exceed $81,474 which is payable in two equal installments of $40,737 upon execution of the Sponsored Study Agreement and $40,737 upon completion of the project with an estimated project timeline of nine months. The Company paid $40,737 on January 13, 2021 which was recorded in prepaid expense to be amortized over the nine-month period. Currently, the project has not been completed due to the delays cause by the Covid-19 pandemic. During the year ended December 31, 2021, the Company fully amortized the prepaid expense of $40,737.
Sublicense amount paid			$ 342,850
Sponsored research agreement, description			The Company paid the first payment of $40,000 pursuant to the payment schedule on the Sponsored Research Agreement on June 15, 2021, second payment of $40,000 on September 9, 2021 and $20,570 on November 18, 2021, third payment of $60,570 on March 1, 2022, which were recorded to prepaid expense and other current assets – current to be amortized over the two-year period. In 2021, the Company amortized $92,855 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized $68,285 of the prepaid expense leaving a prepaid asset of $0 at June 30, 2022.
Company paid cash	$ 92,095
Company paid second payment											$ 50,000
Payment of university									$ 5,000
Agreement, description										the Company paid $5,000 related to this agreement. During the six months ended June 30, 2022, the Company paid $10,000 related to this agreement.
Minimum [Member]
Commitments and Contingencies (Details) [Line Items]
Salary was increased									120,000
Maximum [Member]
Commitments and Contingencies (Details) [Line Items]
Salary was increased									180,000
Sublicense Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Sublicense income, percentage						25.00%
Sublicense agreement amount paid						$ 12,500
Recognized amortization expenses										$ 628
Amortization expense									419
Deferred revenue current portion									3,352
Recognized revenues									1,676	2,514
Master License Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Upfront license fees									$ 1,900,000
JV Agreement [Member]
Commitments and Contingencies (Details) [Line Items]
Pursuant terms, description									(A) the Company shall contribute (1) $225,000 and (2) its expertise and the expertise of its science advisory board and (B) ZTI shall contribute (1) certain rights to certain of its patented technology as set forth in the JV Agreement, (2) a license to the know-how and trade secrets with respect to its Z-pod™ technology for the loading and release of ketamine, (3) ketamine to be used for clinical purposes, (4) reasonable use of its facilities and permits and (5) its expertise and know-how. Pursuant to the JV Agreement, 51% of the interest in the Joint Venture shall initially be owned by the Company and 49% of the interest in the Joint Venture shall initially be owned by ZTI, subject to adjustment in the event of additional contributions by either party. Notwithstanding the foregoing, in no event shall either party own more than 60% of the interest in the Joint Venture.
Dr. James Kuo [Member]
Commitments and Contingencies (Details) [Line Items]
Employment agreement, description					James Kuo entered into an employment agreement (“Kuo Employment Agreement”) for Dr. Kuo to serve as the Vice President of Research & Development. The Kuo Employment Agreement shall be effective as of the date of the agreement and shall automatically renew for a period of one year at every anniversary of the effective date, with the same terms and conditions, unless either party provides written notice of its intention not to extend the term of the Kuo Employment Agreement at least thirty days’ prior to the applicable renewal date. Dr. Kuo shall be paid an annual base salary of $30,000. For each twelve-month period of his employment, Dr. Kuo shall be entitled to a bonus whereby amount and terms shall be in the sole and absolute discretion of the Board of Directors (“Board”) and shall be payable at the Company’s sole option in stock or in cash. In addition, an aggregate of 800,000 incentive stock options were granted under the 2020 Plan to Dr. Kou, exercisable at $0.20 per share and expires on January 31, 2032. The stock options vest as follows: (i) 300,000 stock options upon issuance; (ii) 250,000 vests on October 31, 2022 and; (iii) 250,000 vests on October 31, 2023.
Stock option (in Shares)									800,000
Fair value of stock option									$ 94,914
Risk free interest rate									1.18%
Expected dividend yield									0.00%
Expected term									2 years
Expected volatility									117.00%
Fair value of the unvested stock option									$ 59,322
Stock-based Compensation									23,540
Deferred compensation balance									$ 35,782
Aikido [Member]
Commitments and Contingencies (Details) [Line Items]
Deferred revenue current portion										3,352
Deferred revenue long-term portion										$ 44,134
Columbia University [Member]
Commitments and Contingencies (Details) [Line Items]
Sponsored research agreement, description									If the Company elects to exercise the option, both parties will commence negotiation of a license agreement and will execute a license agreement no later than 3 months after the dated of the exercise of the option. Columbia University and the Company will work towards developing a therapeutic treatment for patients suffering from Alzheimer’s disease to post-traumatic stress disorder. During a one-year period from the date of this agreement, the Company shall pay a total of $1,436,082 to Columbia University for the support of the research according to the payment schedule as follows: (i) 30% at signing, (ii) 30% at four and half months after the start of the project, (iii) 30% at nine months after the start of the project and, (iv)10% at completion of the project. The Company paid the first payment of $430,825 in November 2021 which was recorded to prepaid expense and other current assets – current to be amortized over the estimated project timeline of twelve months. In 2021, the Company amortized $359,021 of the prepaid expense. During the six months ended June 30, 2022, the Company amortized the remaining prepaid expense of $71,804. As of June 30, 2022 and December 31, 2021, prepaid expense related to the sponsored research agreement were $0 and $71,804, respectively.